International | US Home Company Products Resources News & Events Contact You are here: Home / Resources / What is Glaucoma? What is Glaucoma? Glaucoma is a disease that attacks the eye’s optic nerve and can lead to vision loss and eventual blindness if left untreated. It significantly impacts quality of life, in particular for patients with advanced glaucoma and bilateral visual field damage. It affects approximately 80 million people worldwide and is expected to rise to 90 million by 2020. Glaucoma is the second leading cause of blindness after macular degeneration. In a healthy eye, a fluid called aqueous humor flows continuously through the anterior chamber at the front of the eye. Glaucoma is associated with an imbalance between production of aqueous humor and its outflow leading to elevated intraocular pressure (IOP). This increased pressure eventually damages the optic nerve and leads to vision loss over time. The only proven treatment modality for Glaucoma today is to reduce IOP. Reduction of IOP slows down or stops disease progression to preserve visual function. Links: Belgium Glaucoma Society European Glaucoma Society International Glaucoma Association National Eye Research Centre World Glaucoma Association The National Eye Institute The Glaucoma Research Foundation What is Glaucoma? Treatment Options Multimedia © Copyright - iSTAR Medical - Privacy Policy

International | US Home Company Products Resources News & Events Contact You are here: Home / Products / MINIject (MIGS) MINIject (MIGS) MINIjectTM is designed to significantly reduce IOP by enhancing aqueous humour outflow from the anterior chamber to the suprachoroidal space. Implantation is predictable in a single-step procedure using a deployment wheel. Patient Safety Information MINIject exhibits all the advantages of the STAR® material such that it conforms to the eye anatomy, and benefits from sustained drainage efficacy over time due to bio-integration of surrounding tissues into the material. A natural flow speed results, which reduces the incidence of fibrosis, minimises scarring, and increases implant durability. The MINIject first-in-human STAR-I clinical trial showed that the implantation of MINIject resulted in an average of over 40% IOP reduction to a mean of 13.8 mmHg at two years post-surgery. In addition, around half of patients were able to discontinue topical medication usage and remained medication-free at two years. There were no serious adverse events related to the device or the procedure, and no patient required additional glaucoma surgery. The STAR-II European trial showed consistent results at 6-month follow-up. Patient Safety Information INSTRUCTIONS FOR USE Current MINIject (5425033252939) – version 10, 2021-07-14 Overview MINIject (MIGS) STARflo STAR Material Publications Clinical Studies © Copyright - iSTAR Medical - Privacy Policy